NVS has purchased the Dendron plant to ramp this up and there is a competing group in Seattle. I understand this created quite a buzz at ASH.
This could be the future of cancer therapy. It's a very exciting field but keep in mind that the first gene therapy trials led to cancer in immunocompromised patients. It's path to success has many unknowns and it would be years before it can compete with SGEN if at all.
My guess is if there ever were a secondary, it would have a very positive spin to it.
Zack's reports remind me of the old bait and switch scheme. They give you a headline on SGEN and tell you there are a few POS stocks that are better...
Sentiment: Strong Buy
Yes a possibility but why pay the huge premium when they already share the benefits? I would like to see another drug covering a major disease platform. If and when that happens then we are off and running. Right now your estimate of $50 for a takeover seems reasonable IMO.
I agree Kool, and as a longtime investor I remember talk of a poison pill to keep that from happening. Perhaps some of the more astute posters know the details of those provisions?
"Cantor Fitzgerald downgraded its rating on this company from Hold to Sell and changed its price target from $59 to $64." #$%$ does anyone understand this #$%$?